drugset / Trial / NCT00268229
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with daunorubicin and cytarabine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with daunorubicin and cytarabine in treating patients with relapsed acute myeloid leukemia.
Timeline
- Start
- 2003-07
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 300 mg | Oral |
| Subject | Imatinib | Small molecule | 800 mg | Oral |
| Background | Cytarabine | Small molecule | 300 mg/m2 | Intravenous |
| Background | Daunorubicin | Small molecule | 45 mg/m2 | Intravenous |